Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Kadlec Hematology & Oncology
mi
from
Kennewick, WA
Click here to add this to my saved trials
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
University of Colorado
mi
from
Denver, CO
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
University of Colorado
mi
from
Denver, CO
Click here to add this to my saved trials
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Heartland Regional Medical Center
mi
from
St. Joseph, MO
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Heartland Regional Medical Center
mi
from
St. Joseph, MO
Click here to add this to my saved trials
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Pensisula Cancer Institute
mi
from
Newport News, VA
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Pensisula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Arizona Oncology Associates, PC - HOPE
mi
from
Tucson, AZ
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Arizona Oncology Associates, PC-CASA
mi
from
Tucson, AZ
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Arizona Oncology Associates, PC-CASA
mi
from
Tucson, AZ
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Cancer Centers of Florida
mi
from
Orlando, FL
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Cancer Centers of Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Northwest Georgia Oncology Centers, PC
mi
from
Marietta, GA
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
New York Oncology Hematology PC
mi
from
Albany, NY
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center
mi
from
Bronx, NY
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Sciode Medical Associates, PLLC, d.b.a. Eastchester Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Austin Central
mi
from
Austin, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Austin Central
mi
from
Austin, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology/Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology/Methodist Charlton Cancer Ctr.
mi
from
Dallas, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Dallas Presbyterian Hospital
mi
from
Dallas, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Baylor Charles A. Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology - Medical City Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology- Denton South
mi
from
Denton, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Fort Worth 12th Ave.
mi
from
Fort Worth, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Fort Worth 12th Ave.
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology - Memorial City
mi
from
Houston, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology - Memorial City
mi
from
Houston, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology- Lewisville
mi
from
Lewisville, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Paris
mi
from
Paris, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Paris
mi
from
Paris, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Cancer Care Centers of South Texas
mi
from
San Antonio, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Texas Oncology-Tyler
mi
from
Tyler, TX
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Evergreen Hematology & Oncology
mi
from
Spokane, WA
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Northwest Cancer Specialists
mi
from
Vancouver, WA
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Cancer Centers of the Carolinas
mi
from
Greenville, SC
Click here to add this to my saved trials
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
A Phase II, Multicenter, Single-Arm, Feasibility Study of Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Yakima Valley Memorial Hospital/North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer
Delivering an Intervention to Accompany Supportive Care
Status: Enrolling
Updated:  4/11/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer
Delivering an Intervention to Accompany Supportive Care
Status: Enrolling
Updated: 4/11/2016
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
Lombardi Cancer Center-Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer
Status: Enrolling
Updated:  4/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer
Status: Enrolling
Updated: 4/11/2016
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Risk Education and Assessment for Cancer Heredity
Bridging Geographic Barriers: Remote Cancer Genetic Counseling for Rural Women
Status: Enrolling
Updated:  4/12/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Risk Education and Assessment for Cancer Heredity
Bridging Geographic Barriers: Remote Cancer Genetic Counseling for Rural Women
Status: Enrolling
Updated: 4/12/2016
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
Status: Enrolling
Updated:  4/12/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study
Status: Enrolling
Updated: 4/12/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Diindolylmethane in Treating Patients With Breast Cancer
Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study
Status: Enrolling
Updated:  4/13/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Diindolylmethane in Treating Patients With Breast Cancer
Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study
Status: Enrolling
Updated: 4/13/2016
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Newark Beth Israel Medical Center
mi
from
Newark, NJ
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Bronx/Lebanon Hospital
mi
from
Bronx, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Bronx/Lebanon Hospital
mi
from
Bronx, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Jacobi Medical Center
mi
from
Bronx, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Jacobi Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Montefiore Medical Center
mi
from
Bronx, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Brooklyn Hospital Center
mi
from
Brooklyn, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Brooklyn Hospital Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Kings County Hospital
mi
from
Brooklyn, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Kings County Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Lutheran Medical Center
mi
from
Brooklyn, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Lutheran Medical Center
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
University Hospital of Brooklyn at Long Island College Hospital
mi
from
Brooklyn, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
University Hospital of Brooklyn at Long Island College Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Elmhurst Hospital Center
mi
from
Elmhurst, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Queens Hospital Center
mi
from
Jamaica, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Queens Hospital Center
mi
from
Jamaica, NY
Click here to add this to my saved trials
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated:  4/13/2016
Metropolitan Hosp Ctr
mi
from
New York, NY
Tracking & Feedback Registry to Reduce Breast Cancer Treatment Disparities
Implementing a Tracking & Feedback Registry to Allay Cancer Therapy Disparities
Status: Enrolling
Updated: 4/13/2016
Metropolitan Hosp Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor
Status: Enrolling
Updated:  4/13/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor
Status: Enrolling
Updated: 4/13/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Activity & Cognition After Treatment for Breast Cancer
Activity & Cognition After Treatment (ACT) for Breast Cancer
Status: Enrolling
Updated:  4/13/2016
Freer Hall, University of Illinois
mi
from
Urbana, IL
Activity & Cognition After Treatment for Breast Cancer
Activity & Cognition After Treatment (ACT) for Breast Cancer
Status: Enrolling
Updated: 4/13/2016
Freer Hall, University of Illinois
mi
from
Urbana, IL
Click here to add this to my saved trials
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated:  4/14/2016
Mercy Clinic St. Louis Cancer and Breast Institute
mi
from
St. Louis, MO
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated: 4/14/2016
Mercy Clinic St. Louis Cancer and Breast Institute
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated:  4/14/2016
Mercy Hospital St. Louis
mi
from
St. Louis, MO
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® Radiation Therapy Delivery System as the Sole Method of Radiation Therapy or as a Boost for Early Stage Breast Cancer and Ductal Carcinoma In Situ of the Breast
Status: Enrolling
Updated: 4/14/2016
Mercy Hospital St. Louis
mi
from
St. Louis, MO
Click here to add this to my saved trials
Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients
Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients
Status: Enrolling
Updated:  4/14/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients
Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients
Status: Enrolling
Updated: 4/14/2016
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Breast Health in Chinese American Women
A RCT to Promote Mammography Adherence Among Chinese Immigrant Women
Status: Enrolling
Updated:  4/15/2016
UCLA
mi
from
Los Angelas, CA
Breast Health in Chinese American Women
A RCT to Promote Mammography Adherence Among Chinese Immigrant Women
Status: Enrolling
Updated: 4/15/2016
UCLA
mi
from
Los Angelas, CA
Click here to add this to my saved trials